Related Experiment Video
Updated: Aug 14, 2026
14:25
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Selenium binding protein 1 in ovarian cancer
Kuan-Chun Huang1, Dong Choon Park, Shu-Kay Ng
1Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. khuang@rics.bwh.harvard.edu
International Journal of Cancer
|December 29, 2005
Summary
Selenium binding protein 1 (SELENBP1) is significantly down-regulated in ovarian cancer, indicating poor prognosis. Its expression is linked to selenium and androgen pathways, offering potential prognostic insights.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Selenium binding protein 1 (SELENBP1) was identified as a significantly down-regulated protein in ovarian cancer.
- SELENBP1 expression is altered in various ovarian tumor stages, including borderline and invasive cancers.
Purpose of the Study:
- To analyze SELENBP1 expression in ovarian tumors.
- To investigate the prognostic value of SELENBP1 in ovarian cancer.
- To explore the role of selenium and androgen in regulating SELENBP1 expression.
Main Methods:
- Proteome profiling to identify SELENBP1.
- Immunohistochemical assay to quantify SELENBP1 expression in ovarian tissues.
- Cox multivariate analysis for prognostic assessment.
- In vitro studies on human ovarian surface epithelial (HOSE) cells and ovarian cancer cells to assess selenium and androgen effects.
Main Results:
- SELENBP1 expression was reduced in 87% of invasive ovarian cancers and significantly lower in borderline and invasive tumors (p<0.001).
- Lower SELENBP1 expression was a significant indicator of unfavorable prognosis in ovarian cancer (HR=2.18, p=0.009).
- Androgen reduced SELENBP1 in normal HOSE cells but increased it in ovarian cancer cells; selenium showed opposite effects.
Conclusions:
- Reduced SELENBP1 expression is a hallmark of ovarian cancer and a potential prognostic marker.
- Aberrations in SELENBP1 expression suggest dysregulation of selenium/androgen pathways in ovarian cancer.
- SELENBP1's differential response to selenium and androgen in normal versus cancer cells highlights pathway alterations in malignancy.
